Farmaceutické společnosti však dosud ebolu v podstatě ignorovaly, protože vývoj léku pro populace, které si ho nebudou moci dovolit, nesliboval velký zisk.
But until now drug companies had largely ignored Ebola, because there appeared to be little profit in developing a drug for populations that could not afford to pay for it.